Screener
Kymera Therapeutics KYMR Income Statement
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| $0-100% | $65M+466% | $34.37M+55.5% | $2.87M-61.2% | $2.76M-26.1% | ||
| $128.51M+73.4% | $119.48M+52.4% | $98.16M+22.3% | $83.83M+16.7% | $74.09M+22.7% | ||
| $18.72M+8.0% | $21.13M+19.7% | $20.36M+25.1% | $16.94M+3.7% | $17.34M+12.2% | ||
| $147.23M+54.5% | $140.61M+46.4% | $118.52M+22.8% | $100.77M+14.3% | $95.29M+25.6% | ||
| -$147.23M-59.1% | -$75.61M+10.6% | -$84.15M-13.1% | -$97.9M-21.2% | -$92.52M-28.3% | ||
| $15.23M+47.2% | $14.4M+81.2% | $14.92M+68.7% | $10.92M+9.1% | $10.35M+7.4% | ||
| -$132M-60.6% | -$61.21M+20.1% | -$69.23M-5.6% | -$86.98M-22.9% | -$82.18M-31.5% | ||
| -$1.32-40.4% | -$0.62+34.7% | -$0.71+13.4% | -$0.98-10.1% | -$0.94-14.6% | ||
| -$145.21M-60.7% | -$73.58M+10.8% | -$82.13M-13.5% | -$95.86M-21.7% | -$90.37M-28.9% | ||
| -$147.23M-59.1% | -$75.61M+10.6% | -$84.15M-13.1% | -$97.9M-21.2% | -$92.52M-28.3% |
FAQ
- What is Kymera Therapeutics's revenue?
- Kymera Therapeutics (KYMR) generated $102.2M in revenue over the trailing twelve months, up 133.8% year over year.
- Is Kymera Therapeutics profitable?
- Kymera Therapeutics is not currently profitable: it reported a net loss of $349.4M over the trailing twelve months, a -341.8% net margin.
- What is Kymera Therapeutics's earnings per share?
- Kymera Therapeutics's diluted EPS over the trailing twelve months is $-3.63.
- Where does Kymera Therapeutics's income statement data come from?
- Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
